Insider Selling: Vertex Pharmaceuticals Director Sells 1,400 Shares of Stock (VRTX)
Vertex Pharmaceuticals (NASDAQ:VRTX) Director Joshua Boger sold 1,400 shares of the stock on the open market in a transaction that occurred on Wednesday, September 11th. The stock was sold at an average price of $79.61, for a total value of $111,454.00. Following the completion of the sale, the director now directly owns 338,895 shares in the company. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.
A number of analysts have recently weighed in on VRTX shares. Analysts at Oppenheimer initiated coverage on shares of Vertex Pharmaceuticals (NASDAQ:VRTX) in a research note to investors on Wednesday, August 21st. They set an “outperform” rating and a $105.00 price target on the stock. Separately, analysts at Cowen and Company raised their price target on shares of Vertex Pharmaceuticals (NASDAQ:VRTX) from $80.00 to $88.00 in a research note to investors on Tuesday, July 30th. They now have a “market perform” rating on the stock. Finally, analysts at UBS AG raised their price target on shares of Vertex Pharmaceuticals (NASDAQ:VRTX) to $84.00 in a research note to investors on Tuesday, July 30th.
One research analyst has rated the stock with a sell rating, five have given a hold rating and fifteen have given a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus target price of $89.89.
Vertex Pharmaceuticals (NASDAQ:VRTX) traded down 3.87% on Friday, hitting $78.25. The stock had a trading volume of 2,737,381 shares. Vertex Pharmaceuticals has a 1-year low of $38.44 and a 1-year high of $89.96. The stock has a 50-day moving average of $78.4 and a 200-day moving average of $72.21. The company’s market cap is $18.218 billion.
Vertex Pharmaceuticals (NASDAQ:VRTX) last issued its quarterly earnings data on Monday, July 29th. The company reported ($0.26) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.18) by $0.08. The company had revenue of $310.80 million for the quarter, compared to the consensus estimate of $308.02 million. During the same quarter in the prior year, the company posted ($0.31) earnings per share. The company’s quarterly revenue was down 25.7% on a year-over-year basis. Analysts expect that Vertex Pharmaceuticals will post $-2.43 EPS for the current fiscal year.
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is in the business of discovering, developing, manufacturing and commercializing small molecule drugs for the treatment of serious diseases.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.